Recent Company News

• 02:01 PM ET May 11, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 4-May

• 07:09 AM ET May 05, 2026
  

  Hikma Pharmaceuticals, Marius Pharmaceuticals sign Canadian licensing deal for KYZATREX CIII capsules (1438.0000p, +30)

• 04:58 PM ET Apr 23, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 02:04 PM ET Apr 28, 2026
  

  Hikma Pharmaceuticals issues press release on settlement agreement for VYNDAMAX (1397.0000p, 0)

• 10:24 AM ET Apr 28, 2026
  

  Pfizer confirms three settlement agreements in VYNDAMAX (tafamidis) litigation; extends effective patent expiry date to 1-Jun-31 ($26.80, +0.01)

• 08:46 AM ET Apr 28, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:36 AM ET Apr 28, 2026
  

  Pfizer's tafamidis patent suit against Hikma dismissed without prejudice -- court filing ($26.79, 0.00)

• 09:10 PM ET Apr 25, 2026
  

  Pfizer case against Cipla dismissed; one defendant remains in tafamidis IP suit ($27.00, 0.00)

• 12:08 PM ET Apr 24, 2026
  

  BridgeBio Pharma trading higher following incremental settlement in tafamidis (PFE) IP case ($72.93, +1.26)